Equities

Lyra Therapeutics Inc

LYRA:NMQ

Lyra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2676
  • Today's Change0.003 / 0.98%
  • Shares traded367.39k
  • 1 Year change-90.87%
  • Beta-0.0371
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

  • Revenue in USD (TTM)1.82m
  • Net income in USD-101.39m
  • Incorporated2005
  • Employees87.00
  • Location
    Lyra Therapeutics Inc480 Arsenal WayWATERTOWN 02472United StatesUSA
  • Phone+1 (617) 373-4600
  • Fax+1 (302) 655-5049
  • Websitehttps://lyratherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sol Gel Technologies Ltd6.56m-14.92m15.62m36.00--0.4475--2.38-0.5354-0.53540.23551.250.1351--1.59182,194.40-30.72-31.60-34.59-35.49-----227.40-135.76----0.00---59.9864.50-82.52---33.78--
Eom Pharmaceutical Holdings Inc0.00-4.93m15.86m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
IN8BIO, Inc.0.00-31.96m16.08m31.00--1.17-----0.8357-0.83570.000.29330.00----0.00-122.41-74.18-146.35-84.42------------0.0945-------5.21---4.54--
Traws Pharma Inc226.00k-137.05m16.10m16.00------71.25-138.17-138.170.25576.030.0092--12.9114,125.00-557.63-63.43-896.39-85.72-----60,641.15-3,257.92----0.00--0.00-28.720.0844------
Tenax Therapeutics Inc0.00-12.57m16.16m5.00--1.05-----22.35-22.350.004.530.00----0.00-101.95-199.16-113.79-285.64-----------95.940.0305------30.21------
Minerva Neurosciences Inc0.00-3.31m16.39m9.00---------0.4357-0.43570.00-3.100.00----0.00-6.25-49.89-6.75-52.39-------442.65------------6.55------
Geovax Labs Inc300.68k-26.92m16.62m17.00------55.29-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
Microbot Medical Inc0.00-10.44m16.83m22.00--2.69-----0.81-0.810.000.37930.00----0.00-113.94-53.28-133.34-62.65------------0.00------18.44---31.76--
Synlogic Inc3.17m-56.16m16.92m6.00--1.06--5.34-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Kairos Pharma Ltd0.00-2.01m17.21m-----------0.1562-0.15620.00-0.20670.00-------199.80-----------------15.58---------72.57------
Lyra Therapeutics Inc1.82m-101.39m17.52m87.00--0.5655--9.62-1.61-1.610.02940.47330.0165----20,681.82-92.07-58.01-108.51-68.69-----5,570.88-6,235.31----0.00--14.314.60-13.39--95.14--
Kazia Therapeutics Ltd (ADR)14.84k-13.47m17.76m12.00--1.65--1,196.48-8.17-8.170.00813.480.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Cocrystal Pharma Inc0.00-17.93m17.91m12.00--1.03-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Finch Therapeutics Group Inc0.00-14.17m18.95m18.00--1.33-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Aprea Therapeutics Inc1.31m-13.51m19.28m7.00--0.8791--14.71-2.81-2.810.26464.280.0498----187,262.90-51.30-68.66-60.22-77.19-----1,030.42-42,112.84----0.00------87.32--90.61--
Data as of Nov 08 2024. Currency figures normalised to Lyra Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

40.89%Per cent of shares held by top holders
HolderShares% Held
Perceptive Advisors LLCas of 14 Aug 202412.76m19.49%
Citadel Advisors LLCas of 30 Jun 20244.77m7.29%
BlackRock Fund Advisorsas of 30 Jun 20242.82m4.31%
The Vanguard Group, Inc.as of 30 Jun 20241.67m2.55%
Ikarian Capital LLCas of 30 Jun 20241.06m1.62%
Acadian Asset Management LLCas of 30 Jun 2024985.63k1.51%
Parametric Portfolio Associates LLCas of 30 Jun 2024766.12k1.17%
Geode Capital Management LLCas of 30 Jun 2024755.10k1.15%
Two Sigma Advisers LPas of 30 Jun 2024681.60k1.04%
Two Sigma Investments LPas of 30 Jun 2024490.86k0.75%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.